In the dynamic and ever-evolving stock market, certain stocks manage to make their mark through effective strategies and robust financial performance. One such star performer is NVAX, which has been successfully leveraging a market-neutral strategy, encompassing both technical and fundamental analysis (TA&FA), to generate impressive returns. This strategy has reaped a 9.04% return for NVAX, demonstrating the strength of its market navigation.
A recent promising signal comes from the Moving Average Convergence Divergence (MACD) for NVAX. The MACD, a trend-following momentum indicator, turned positive on July 10, 2023. This significant milestone indicates a bullish trend, suggesting that the company's shares are on an upward trajectory.
Historically, NVAX's performance following a positive MACD has been robust. Looking back, NVAX's MACD turned positive in 44 instances. In 42 of these cases, the stock continued to rise over the subsequent month. This strikingly high rate implies a 90% likelihood of continued upward movement, affirming the robustness of NVAX's financial performance.
The MACD is a key technical indicator that traders and investors use to identify potential buying and selling opportunities. When the MACD line crosses above the signal line, it is generally considered a bullish sign that could indicate a good time to buy. For NVAX, this cross occurred on July 10, 2023, adding a strong technical factor to its positive fundamental outlook.
The market-neutral strategy of TA&FA has helped NVAX thrive even in choppy market conditions. The positive MACD turning point further strengthens the case for NVAX's continued growth. This unique blend of analytical strategies has helped NVAX maintain its momentum in the face of market volatility, carving out a niche for itself in the realm of popular stocks.
While past performance is not a guarantee of future results, the historical trend provides a compelling case for NVAX. The company's commitment to leveraging both technical and fundamental analysis sets it apart, offering a unique lens through which to view its potential for sustained growth. Given the consistent trend of outperformance following a positive MACD turn, the signs point to continued success for NVAX in the foreseeable future.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on September 20, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 11, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on September 12, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
NVAX moved below its 50-day moving average on September 11, 2023 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVAX broke above its upper Bollinger Band on September 06, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 130 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (49.505) is normal, around the industry mean (22.685). P/E Ratio (0.000) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.368) is also within normal values, averaging (316.663).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in development of novel recombinant vaccines
|MFs / NAME||Price $||Chg $||Chg %|
|MainStay Epoch International Choice Smpl|
|X-Square Balanced Fund, LLC Instl|
|Lord Abbett Fundamental Equity R2|
|Eaton Vance Atlanta Capital SMID-Cap R6|
|American Century Real Estate R|
A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.